Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes
Authors' conclusion
In patients with type 2 diabetes in the U.K., GLP-1RAs were not associated with a lower risk of cirrhosis compared with DPP-4 inhibitors in patients with type 2 diabetes. However, SGLT-2 inhibitors were associated with a lower risk of cirrhosis compared with DPP-4 inhibitors.
Study context
- Population
- Patients with T2D, UK Clinical Practice Research Datalink linked with hospital and national statistics databasestwo separate cohorts
- Participants
- 25,516 / 186,752 / 33,161 / 124,431
- Exposure
- GLP-1 RA vs DPP-4i; SGLT2i vs DPP-4i
- GLP-1RAsn = 25,516
- DPP-4 inhibitorsn = 186,752reference
- SGLT-2 inhibitorsn = 33,161
- DPP-4 inhibitorsn = 124,431reference
- Outcome
- Cirrhosis
Methodological detailsactive comparator, new-user approach, propensity score fine stratification weighting
- Active comparator, new-user approach
- Propensity score fine stratification weighting
Main finding
As reported in the abstract
Hazard ratio (95% CI)
GLP-1RAsvs DPP-4 inhibitors (GLP-1RA cohort)not associated
0.90(0.68–1.19)
SGLT-2 inhibitorsvs DPP-4 inhibitors (SGLT-2 cohort)reduced incidence
0.64(0.46–0.90)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Decompensated cirrhosis (SGLT-2 cohort)SGLT-2 inhibitorsvs DPP-4 inhibitors (SGLT-2 cohort) | 0.74 (0.54–1.00) | |
| 0.512Hazard ratio (log scale) |
Secondary outcomes (decompensated cirrhosis, hepatocellular carcinoma, liver-related mortality), GLP-1RA cohort
- GLP-1RAs not associated with the secondary outcomes
Hepatocellular carcinoma and liver-related mortality (SGLT-2 cohort)
- SGLT-2 inhibitors not associated with a lower risk of hepatocellular carcinoma or liver-related mortality
Original publication
Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →